| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The target of 4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid is the thiol group on antibodies or payloads. The PDS group reacts with free thiols to form a disulfide bond. The disulfide bond is cleaved by intracellular glutathione (GSH), releasing the payload. The carboxylic acid allows for conjugation to amine-containing ligands. The linker itself does not bind to a biological receptor; it serves as a cleavable connection tool for ADC synthesis.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1].
In vitro activity of 4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid is evaluated for its conjugation efficiency and cleavage. The linker is reacted with a thiol-containing antibody and an amine-containing payload. The reaction is monitored by HPLC. The resulting ADC is tested for its binding affinity to the target antigen and its cytotoxicity against antigen-positive cancer cells. |
| ln Vivo |
In vivo activity of ADCs containing 4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid is assessed in animal models. The linker's stability in circulation and selective cleavage within tumor cells are critical for achieving a favorable therapeutic index. In vivo studies involve administering the ADC to tumor-bearing mice and monitoring tumor growth inhibition.
|
| Enzyme Assay |
For non-cellular assays, 4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid is reacted with a thiol-containing antibody in a buffer at pH 6.5-7.5 to form a disulfide bond. The carboxylic acid is then activated with EDC or NHS and reacted with an amine-containing payload in a buffer at pH 7-8. The resulting ADC is purified and characterized. The disulfide bond's cleavage is tested by adding glutathione.
|
| Cell Assay |
In vitro cell experiments involve incubating antigen-positive cancer cells with the ADC. The cells are analyzed for binding, internalization, and cytotoxicity. The disulfide bond is reduced by intracellular GSH, releasing the payload. Cell viability is measured using standard assays. The results are compared with those of a non-targeted control ADC.
|
| Animal Protocol |
In vivo animal experiments with ADCs containing 4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid typically use xenograft tumor models. The ADC is administered intravenously, and tumor volume is measured regularly. The linker's stability is assessed by analyzing plasma for free payload. The efficacy of the ADC is evaluated by comparing tumor growth in treated and control groups.
|
| References |
| Molecular Formula |
C₁₁H₁₅NO₂S₂
|
|---|---|
| Molecular Weight |
257.37
|
| Exact Mass |
257.054
|
| CAS # |
1537891-69-2
|
| PubChem CID |
88565203
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
416.1±41.0 °C at 760 mmHg
|
| Flash Point |
205.5±27.6 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.600
|
| LogP |
3.43
|
| tPSA |
101
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
16
|
| Complexity |
234
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C(C)(C)CCC(=O)O)SC1C=CC=CN=1
|
| InChi Key |
FCKSMEZVBFTODF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H15NO2S2/c1-11(2,7-6-10(13)14)16-15-9-5-3-4-8-12-9/h3-5,8H,6-7H2,1-2H3,(H,13,14)
|
| Chemical Name |
4-methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid
|
| Synonyms |
4Methyl4(pyridin2yldisulfanyl)pentanoic acid; 4 Methyl 4 (pyridin 2 yldisulfanyl)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8855 mL | 19.4273 mL | 38.8546 mL | |
| 5 mM | 0.7771 mL | 3.8855 mL | 7.7709 mL | |
| 10 mM | 0.3885 mL | 1.9427 mL | 3.8855 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.